BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37148821)

  • 1. Generation and characterization of induced pluripotent stem cell lines from two patients with recessive dystrophic epidermolysis Bullosa.
    Vincent C; Lefort N; Hamlin M; Banal C; Hovnanian A; Izmiryan A
    Stem Cell Res; 2023 Jun; 69():103104. PubMed ID: 37148821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa.
    Berthault C; Gaucher S; Gouin O; Schmitt A; Chen M; Woodley D; Titeux M; Hovnanian A; Izmiryan A
    J Invest Dermatol; 2024 Jun; 144(6):1322-1333.e13. PubMed ID: 38043638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
    Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
    J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of the induced pluripotent stem cell line (ZSPHARi001-A) from a patient with recessive dystrophic epidermolysis bullosa carrying compound heterozygous mutation in the COL7A1 gene.
    Zhang Y; Fan J; Lu G; Xu G; Lv Q
    Stem Cell Res; 2022 Apr; 60():102672. PubMed ID: 35121199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically corrected iPSCs as cell therapy for recessive dystrophic epidermolysis bullosa.
    Wenzel D; Bayerl J; Nyström A; Bruckner-Tuderman L; Meixner A; Penninger JM
    Sci Transl Med; 2014 Nov; 6(264):264ra165. PubMed ID: 25429058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs.
    Osborn MJ; Newby GA; McElroy AN; Knipping F; Nielsen SC; Riddle MJ; Xia L; Chen W; Eide CR; Webber BR; Wandall HH; Dabelsteen S; Blazar BR; Liu DR; Tolar J
    J Invest Dermatol; 2020 Feb; 140(2):338-347.e5. PubMed ID: 31437443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of patients with recessive dystrophic epidermolysis bullosa in the Netherlands: expansion of the mutation database and unusual phenotype-genotype correlations.
    van den Akker PC; van Essen AJ; Kraak MM; Meijer R; Nijenhuis M; Meijer G; Hofstra RM; Pas HH; Scheffer H; Jonkman MF
    J Dermatol Sci; 2009 Oct; 56(1):9-18. PubMed ID: 19665875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa.
    Sebastiano V; Zhen HH; Haddad B; Bashkirova E; Melo SP; Wang P; Leung TL; Siprashvili Z; Tichy A; Li J; Ameen M; Hawkins J; Lee S; Li L; Schwertschkow A; Bauer G; Lisowski L; Kay MA; Kim SK; Lane AT; Wernig M; Oro AE
    Sci Transl Med; 2014 Nov; 6(264):264ra163. PubMed ID: 25429056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induced pluripotent stem cell (iPSC) line MLi-004A derived from a patient with recessive dystrophic epidermolysis bullosa (RDEB).
    Ropret S; Jeriha J; Sorčan T; Rogar M; Zemljič Jokhadar Š; McGrath JA; Ilic D; Liovic M
    Stem Cell Res; 2021 Aug; 55():102463. PubMed ID: 34284275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel homozygous splice site mutation in COL7A1 in a Chinese patient with severe recessive dystrophic epidermolysis bullosa and squamous cell carcinoma.
    Huang L; Wong YP; Burd A
    Int J Dermatol; 2011 Jan; 50(1):52-6. PubMed ID: 21182502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induced pluripotent stem cell (iPSC) line MLi005-A derived from a patient with dominant dystrophic epidermolysis bullosa (DDEB).
    Ropret S; Khurana P; Fabčič T; Cvetkovska J; Trobec A; Jokhadar ŠZ; Ilic D; McGrath JA; Guttmann-Gruber C; Liovic M
    Stem Cell Res; 2024 Mar; 75():103306. PubMed ID: 38271763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa.
    Hong SA; Kim SE; Lee AY; Hwang GH; Kim JH; Iwata H; Kim SC; Bae S; Lee SE
    Mol Ther; 2022 Aug; 30(8):2664-2679. PubMed ID: 35690907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mild recessive dystrophic epidermolysis bullosa associated with two compound heterozygous COL7A1 mutations.
    von Bartenwerffer W; Has C; Arin MJ; Tantcheva-Poór I; Kreuter A; Kremer K; Arshah T; Hoffmann M; Eming SA; Kohlhase J; Krieg T; Bruckner-Tuderman L; Hartmann K
    Eur J Dermatol; 2011; 21(2):170-2. PubMed ID: 21382783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients.
    Woodley DT; Cogan J; Hou Y; Lyu C; Marinkovich MP; Keene D; Chen M
    J Clin Invest; 2017 Aug; 127(8):3028-3038. PubMed ID: 28691931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.
    Jacków J; Titeux M; Portier S; Charbonnier S; Ganier C; Gaucher S; Hovnanian A
    J Invest Dermatol; 2016 Jul; 136(7):1346-1354. PubMed ID: 26994967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The inversa type of recessive dystrophic epidermolysis bullosa is caused by specific arginine and glycine substitutions in type VII collagen.
    van den Akker PC; Mellerio JE; Martinez AE; Liu L; Meijer R; Dopping-Hepenstal PJ; van Essen AJ; Scheffer H; Hofstra RM; McGrath JA; Jonkman MF
    J Med Genet; 2011 Mar; 48(3):160-7. PubMed ID: 21113014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of collagen VII sequence variants found in Australasian patients with dystrophic epidermolysis bullosa reveals nine novel COL7A1 variants.
    Dang N; Klingberg S; Marr P; Murrell DF
    J Dermatol Sci; 2007 Jun; 46(3):169-78. PubMed ID: 17425959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa.
    Tolar J; McGrath JA; Xia L; Riddle MJ; Lees CJ; Eide C; Keene DR; Liu L; Osborn MJ; Lund TC; Blazar BR; Wagner JE
    J Invest Dermatol; 2014 May; 134(5):1246-1254. PubMed ID: 24317394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa.
    Tolar J; Xia L; Riddle MJ; Lees CJ; Eide CR; McElmurry RT; Titeux M; Osborn MJ; Lund TC; Hovnanian A; Wagner JE; Blazar BR
    J Invest Dermatol; 2011 Apr; 131(4):848-56. PubMed ID: 21124339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa.
    Dang N; Murrell DF
    Exp Dermatol; 2008 Jul; 17(7):553-68. PubMed ID: 18558993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.